Company intelligence / Profile preview

Shanghai Yuan Song Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

YuanSong Biotech is a Shanghai-based clinical-stage biotechnology company specializing in the development of next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. The company leverages its proprietary platform to enhance the fitness and persistence of TILs, aiming to overcome the limitations of traditional cell therapies in treating epithelial cancers. Its lead program, YS-TIL01, is currently being evaluated for safety and efficacy in patients with advanced solid tumors. YuanSong Biotech is supported by prominent venture capital firms and focuses on integrating advanced gene editing and cell culture techniques to improve therapeutic outcomes.

Therapeutic areas: Oncology
Modalities: Cell therapyTumor-infiltrating lymphocytes
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Yuan Song Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yuan Song Biotechnology.

Explore the full profile